|
![]() |
|
|
Butalbital
drug data and news
Butalbital drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Butalbital | ||
| Brand Names/Synonyms | Acid; Alisobumal; Allylbarbital; Allylbarbitone; Allylbarbituric Acid; Allylisobutylbarbital; Allylisobutylbarbituric Acid; Butalbarbital; Butalbital; Butalbital-Permethylated; Isobutylallylbarbituric Acid; Isobutylallylbarturic Acid; Itobarbital; O,O-Dimethylylbutabarbital; Optalidon; Profundal; Sandoptal; Tetrallobarbital | ||
| Indication | For the relief of the symptom of complex tension (or muscle contraction) headache (esp. Fioricet) | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Butalbital, a barbiturate, is used in combination with acetaminophen or aspirin and caffeine for its sedative and relaxant effects in the treatment of tension headaches, migraines, and pain. Barbiturates act as nonselective depressants of the central nervous system (CNS), capable of producing all levels of CNS mood alteration from excitation to mild sedation, hypnosis, and deep coma. In sufficiently high therapeutic doses, barbiturates induce anesthesia. | ||
| Mechanism Of Action | Butalbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. | ||
| Butalbital News (When available) |
FIORICET,or it's genenic Butalbital, is a non-nar Feb 19, 2006 COMPLETE BREAKDOWN OF WWE WELLNESS PROGRAM Feb 27, 2006 Investigation leads to firing of town cop Feb 22, 2006 Big Stone Gap woman sentenced in DUI fatality Jan 31, 2006 Big Stone Gap woman sentenced in DUI fatality Jan 31, 2006 Jury to hear 1998 murder case Jan 21, 2006 Avitar Enters Rapidly Expanding Oral Fluid-Based Laboratory Drug ... Nov 29, 2005 Ask the Clinician: Answers to Readers' Questions Nov 28, 2005 URL/Mutual Tracking to Achieve Another Record Year in Sales ... Sep 12, 2005 Blood alcohol levels questioned Aug 20, 2005 Doctor practicing at CRMC under state review Aug 17, 2005 Medication Overuse Headache: When Meds Cause the Pain Aug 19, 2005 Doctor faces sex, narcotics charges Jul 23, 2005 Able unable to meet investors Jul 4, 2005 Tramadol 50mg, Imitrex (Sumatriptan), Butalbital APAP w/Caffeine ... Apr 5, 2005 Tramadol 50mg, Imitrex (Sumatriptan), Butalbital APAP w/Caffeine ... Apr 5, 2005 | ||
| Dosage Forms | TABLETS | ||
| Drug_Category | Analgesics; ATC:N05CA | ||
| Absorption | Well absorbed from the gastrointestinal tract | ||
| Interactions |
-->Interactions for Butalbital: The CNS effects of butalbital may be enhanced by monoamine oxidase (MAO) inhibitors. Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression. Drug/Laboratory Test Interactions Acetaminophen may produce false-positive test results for urinary 5-hydroxyindoleacetic acid. | ||
| Toxicity | Symptoms attributable to acute barbiturate poisoning include drowsiness, confusion, and coma; respiratory depression; hypotension; shock. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 5-(2-methylpropyl)-5-prop-2-enyl-hexahydropyrimidine-2,4,6-trione | ||
| Chemical Formula | C11H16N2O3 | ||
| Molecular Weight | 224.256 g/mol | ||
| Smiles String | CC(C)CC1(C(=O)NC(=O)NC1=O)CC=C | ||
| Melting Point | 138-139 °C | ||
| Water Solubility | 1700 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 1.429 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Primarily hepatic. Urinary excretion products included parent drug (about 3.6% of the dose), 5-isobutyl-5-(2,3-dihydroxypropyl) barbituric acid (about 24% of the dose), 5-allyl-5(3-hydroxy-2-methyl-1-propyl) barbituric acid (about 4.8%) | ||
| Half Life | 35 hours | ||
| Protein Binding [%] | 45% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.rxlist.com/cgi/generic/esgic.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00266 | ||
| CAS Registry Number | 77-26-9 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:149431 | ||
| PharmGKB ID | PA448695 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 176192 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |